What China’s new patent laws mean for life sciences
On June 1, 2021, the Chinese government implemented crucial changes to its patent laws, hoping to create better protections for national and international inventors.
Flatwing fails to shift attorney fees to Pfizer unit, Anacor
Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.
Barnes & Thornburg opens Boston office with new partners
Law firm Barnes & Thornburg has announced the opening of a Boston office, its twentieth in the US, with six partners.
English High Court strikes out bad faith ‘Revolax’ TM
A Warrington-based distributor of aesthetic and cosmetic products has lost its UK trademark for a dermal filler brand after the English High Court found it to have registered the brand in bad faith.
SPCs outlive patent protections in 91% of cases, new report reveals
Supplementary protection certificates outlive medicinal patents in more than nine in ten cases, a new report has found.
Pharma company fails to block €140m licence payment
Taiwanese pharmaceutical company PharmaEssentia Corporation has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals.
LSPN Connect: The battle for COVID-19 vaccines
With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.
LSIPR, Gowling WLG team up for biologics survey
Life Sciences IP Review has partnered with international law firm Gowling WLG to launch the Patent Litigation Survey to appraise the patent trends in biologics, biosimilars and next generation therapies.
SCOTUS won’t resuscitate Amarin’s Vascepa patents
Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.
Bio-Rad asks for review of DNA patent ruling
Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.
